Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Vulnerability in
Ovarian Cancer

About Robert Rottapel

"Dr. Rottapel is a Senior Scientist at the Princess Margaret Cancer Centre where he holds the Amgen Chair for Cancer Research. He is a Professor in the Departments of Medicine, Immunology and Medical Biophysics at the University of Toronto. After completing his medical studies at George Washington University, the NIH and UCLA, he pursued his postdoctoral studies with Allan Bernstein at the Lunenfeld Research Institute in Toronto and with Patrice Dubreuil at INSERM, France. Dr. Rottapel is a clinical rheumatologist at St. Michael's Hospital, University of Toronto. His clinical expertise is in monogenic autoinflammatory disorders and the autoimmune adverse effect resulting from checkpoint inhibitors in cancer patients.

Dr. Rottapel’s research interests lies in the elucidation of signal transduction pathways in cancer, immune and bone cells. He has focussed on developing a comprehensive map of ovarian cancer essential genes using whole genome RNAi and CRISPR technology. This approach has provided insight into novel drivers resulting from the widespread gene copy number aberrations observed in ovarian cancer and the identification of emergent vulnerabilities associated with adaptation pathways required to buffer cancer associated stress states. Several of these targets are being developed for potential new therapeutic strategies in ovarian and pancreatic cancer. A second area of interest has been the elucidation of the molecular basis for a rare autosomal human disease called Cherubism. The adapter protein 3BP2 is mutated in Cherubism. The Rottapel lab has shown that 3BP2 has pleiotrophic function controlling bone homeostasis, immune cell function and scavenger receptor activation."

Robert Rottapel on the web

• The Rottapel Lab

• Ontario Institute for Cancer Research

• University of Toronto

• Pubmed

• Google Scholar

• LinkedIn

• Dr. GPCR